Advanced Strategies to Improve CVD Outcomes in Patients with Chronic Coronary Artery Disease and Peripheral Artery Disease


Program Dates: December 28, 2019 - December 27, 2020
Credits: 1.5 AMA PRA Category 1 Credits™; 1.5 CNE Contact Hours


Advanced Strategies to Improve CVD Outcomes in Patients with Chronic Coronary Artery Disease and Peripheral Artery Disease

Program Overview

This CME/CE program, derived from content presented at the 2019 American Heart Association Scientific Sessions in Philadelphia, Pennsylvania, will highlight advanced strategies for improving cardiovascular disease (CVD) outcomes in patients with chronic coronary artery disease (CAD) and peripheral artery disease (PAD). The expert faculty, chaired by Dr. Christopher P. Cannon, will first provide an introduction and state of the science of CAD and PAD, and transition into a review of the role of anticoagulants in preventive cardiology. Recent clinical trial data, particularly that of anticoagulants and aspirin combination therapeutic strategies, will be reviewed as it relates to clinical decision making for healthcare professionals. Finally, the interactive panel will cover the role of the interprofessional team in providing optimal, tailored treatment plans to improve CVD outcomes and quality of life for patients with CAD and PAD.

Target Audience

Cardiologists, primary care providers, nurses, NPs, PAs, pharmacists, and other members of an interprofessional care team involved in the management of CAD/PAD

Agenda

I. Introduction 
II. The Role of Anticoagulants in Preventive Cardiology in CAD/PAD 
III. A Clinical Update on Newer Trial Data for Anticoagulants + Aspirin Combination Therapeutic Strategies for the Treatment of CAD/PAD
IV. Interactive Panel Discussion
V. Developing Optimal Treatment Plans that Prevent Cardiovascular Events in Patients with CAD/PAD
VI. Interactive Panel Discussion

Learning Objectives

  1. Recognize the role of anticoagulants in preventive cardiology in CAD/PAD
  2. Analyze the most current data for anticoagulants + aspirin combination therapeutic strategies for the treatment of CV events in CAD/PAD
  3. Develop collaborative treatment strategies to prevent cardiovascular events in patients with CAD/PAD

Faculty

Christopher P. Cannon, MD (Course Chair)
Education Director, CV Innovation Cardiovascular Division,
Brigham and Women’s Hospital
Professor of Medicine, Harvard Medical School
Boston, MA

 

Joshua Beckman, MD
Professor of Medicine
Director, Section of Vascular Medicine
Vanderbilt Heart and Vascular Institute (VHVI)
Vanderbilt University School of Medicine
Nashville, TN

Marc P. Bonaca, MD, MPH
Colorado Prevention Center
Vascular Medicine Section, Cardiovascular Division
Associate Professor of Medicine
University of Colorado School of Medicine
Aurora, CO

Center Director
Brigham and Women’s – Dartmouth Hitchcock
AHA SFRN in Peripheral Vascular Disease
Harvard University
Boston, MA

Manesh R. Patel, MD
Chief, Division of Cardiology
Co-Director Duke Heart Center
Duke University
Durham, NC

 

Disclosures of Conflict of Interest

All faculty AND staff involved in the planning, review or presentation of continuing education activities sponsored / provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material.  Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.  All additional planning committee members, reviewers, Purdue and AcademicCME staff have nothing to disclose.

Faculty Relationship Identified With:

Christopher P. Cannon, MD

Consultant/Advisor: Aegerion Pharmaceuticals Inc.; Alnylam Pharmaceuticals; Amarin Corporation; Amgen Inc.; Boehringer Ingelheim; Bristol-Myers Squibb; Corvidia Therapeutics; Eisai, Inc.; Innovent; Janssen Scientific Affairs, LLC.; Kowa Pharmaceuticals; Merck & Co.; Pfizer Inc.; Regeneron Pharmaceuticals; Sanofi

Grants/Research Support: Amgen Inc.; Boehringer Ingelheim Bristol-Myers Squibb; Daiichi Sankyo; Janssen Scientific Affairs, LLC.; Merck & Co.

Joshua A. Beckman, MD

Consultant/Advisor: Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Bristol-Myers Squibb; Merck & Co.; Sanofi; Novartis Pharmaceuticals Corporation

Marc P. Bonaca, MD, MPH

Consultant/Advisor: Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Janssen Scientific Affairs, LLC.; Merck & Co.; Novo Nordisk; Pfizer Inc.; Regeneron

Grant/Research Support: Amgen Inc.; AstraZeneca Pharmaceuticals; Bayer AG; Merck & Co.; Novo Nordisk; Pfizer Inc.; Sanofi

Manesh R. Patel, MD

Consultant/Advisor: Heartflow

Grant/Research Support: AstraZeneca Pharmaceuticals; Bayer AG; Janssen Scientific Affairs, LLC.; Procyrion

Advisory Board Membership: AstraZeneca Pharmaceuticals; Bayer AG; Janssen Scientific Affairs, LLC.; Mytonomy, Inc.; Procyrion

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and AcademicCME, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements

Purdue University College of Pharmacy designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This program has been approved for 1.5 contact hours.

Financial Support

This activity has been supported by an independent educational grant from Janssen Scientific Affairs LLC.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Janssen Scientific Affairs LLC. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].

BUTTON

Provided by: AcademicCME-web